NEO · NeoGenomics, Inc.

NeoGenomics delivered a strong first quarter in 2026, marked by double-digit revenue growth and significant operational improvements. Consolidated revenue rose 11% year-over-year to a record $187 million, primarily fueled by a 14% increase in Clinical revenue, which includes 26% growth in Next-Generation Sequencing (NGS). The company successfully reduced its GAAP net loss by 34% to $17 million, compared to $26 million in the prior year period, while achieving positive Adjusted EBITDA of $9 million, a 27% improvement. Operating expenses decreased by 2% to $99 million, reflecting disciplined cost management alongside revenue expansion. From a strategic perspective, management highlighted the launch of the RaDaR ST MRD assay, targeting a large, underpenetrated market, and a favorable MolDX coverage decision for PanTracer LBx. These operational wins support the company's raised full-year 2026 revenue guidance, now expected to be between $797 million and $803 million, up from the initial range. The company maintains a solid liquidity position with $146 million in cash and marketable securities.